The honest starting point for synthetic peptide work is that most short peptides do not fold. In water, a peptide of ten or twenty residues usually exists as a rapidly interconverting ensemble of conformations rather than one shape. That matters, because a peptide copied out of a folded protein will not automatically reproduce the structure it had inside that protein. This page covers what sets structure in short peptides, how to tell what you have, and what to do when your experiment needs a defined conformation.
A folded structure has to pay for itself. Fixing a chain into one conformation costs conformational entropy, and that cost has to be covered by the hydrogen bonds, hydrophobic contacts and electrostatic interactions the fold creates. A short chain simply cannot form enough of them. A protein domain of a hundred residues can bury a hydrophobic core; a twelve-residue peptide cannot, so the balance tips towards the disordered ensemble.
This is why an isolated helix taken from a protein is usually only marginally helical on its own. In the protein it was held in place by the rest of the structure. Removed from that context, it loses the interactions that stabilized it.
| Factor | Effect |
|---|---|
| Residue propensity | Alanine, leucine and glutamate favour helix; proline and glycine break it. Proline and glycine instead favour turns. Beta-branched and aromatic residues favour extended, sheet-like conformations. |
| Covalent constraint | A disulfide bond, a lactam bridge, a head-to-tail cycle or a hydrocarbon staple physically restricts the chain and is the most reliable way to enforce a conformation. |
| Solvent | Helix-promoting cosolvents such as trifluoroethanol, and membrane-mimicking detergents such as SDS micelles, can raise helix content substantially. A peptide that is helical only in those conditions is not necessarily helical in your assay buffer. |
| pH and ionic strength | Change the charge on acidic and basic side chains, which can either stabilize or disrupt helices and salt bridges. |
| Self-association | Hydrophobic and amyloidogenic sequences gain structure by assembling with each other, often into beta-sheet aggregates. This is structure, but usually not the structure you wanted. |
| Binding to a partner | Many peptides are disordered free in solution and adopt a defined conformation only on binding their target. The bound state is the relevant one for an interaction study. |
Disordered is not the same as useless
Plenty of peptide applications do not need a folded peptide. Linear epitope mapping, antibody immunogens, protease substrates and mass spectrometry standards all work precisely because the peptide is an accessible, extended sequence. Conformation becomes the limiting factor when you are trying to reproduce a structured binding surface.
When the biology depends on shape, the answer is to build the constraint into the molecule rather than hope for it in solution. Common approaches, in roughly increasing order of effort:
If conformation matters, say so, and say which structure you are aiming for and in what buffer the peptide will be used. A peptide intended to reproduce a helical binding surface is a different design from the same sequence intended as a linear epitope, even though the letters are identical. For disulfide-containing peptides, give us the pairing you want rather than only the cysteine positions. Paste a sequence into our sequence analysis tool to review length, charge and hydrophobicity before ordering.
Review length, charge, hydrophobicity and other properties before you order.
Most do not. In water a peptide of ten to twenty residues usually exists as a rapidly interconverting ensemble of conformations rather than a single folded shape, because a short chain cannot form enough stabilizing interactions to pay the entropic cost of folding.
Usually not. In the protein the region was held in place by the surrounding structure. Removed from that context an isolated helix is typically only marginally helical on its own.
Circular dichroism in the far UV is the standard first measurement and distinguishes helix, sheet and disordered ensembles. NMR gives residue-level detail. Run the measurement in the buffer you will actually use.
Build the constraint into the molecule: terminal capping, disulfide cyclization, head-to-tail or side-chain cyclization, stapling, or sequence redesign towards higher helix propensity.
Not in your assay. Helix-promoting cosolvents and detergent micelles raise helix content, but a peptide that is helical only under those conditions is not necessarily helical in a plain aqueous buffer.
Research use only. LifeTein peptides and proteins are supplied for laboratory research use. They are not for human or veterinary use, and not for diagnostic or therapeutic use. See our research use policy.